Aurora Cannabis Announces Intention to Launch Takeover Bid for CanniMed Therapeutics Inc.
Provides Comments on CanniMed’s Poison Pill Tactic
- Aurora’s proposed offer currently valued at $24.00 per CanniMed share
- Represents a 56.9% premium to CanniMed’s closing price prior to Aurora’s takeover proposal announcement
- Lock-up agreements already in place with CanniMed’s 3 largest shareholders for 38% of CanniMed shares
- CanniMed’s intention to acquire Newstrike is highly conditional and oppressive to CanniMed shareholders in light of Aurora’s proposed offer
VANCOUVER, Nov. 20, 2017 /CNW/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSX: ACB) announced today that, further to its press release of November 14, 2017, it intends to make an offer (the “Offer”) to purchase all of the issued and outstanding common shares (the “CanniMed Shares”) of CanniMed Therapeutics Inc. (“CanniMed”) (TSX: CMED) for consideration consisting of common shares of Aurora (the “Aurora Shares”).
The Offer will provide holders of CanniMed Shares with 4.52586207 Aurora Shares for each CanniMed Share, subject to a maximum of $24.00 per CanniMed Share (the “Cap Price”). If the market value for 4.52586207 Aurora Shares is more than the Cap Price (based on the 20-day VWAP of Aurora Shares on the earlier of the expiry date for the Offer and the date on which the conditions to the Offer have been satisfied), then Aurora will adjust the number of Aurora Shares offered as consideration in the Offer, such that the consideration payable for each CanniMed Share is equal to the Cap Price.
The Offer Price, which would currently be equivalent to the Cap Price of $24.00 given Aurora’s closing share price of $5.51 on November 17, 2017, represents a 56.9% premium over the closing price of CanniMed Shares on November 14, 2017, the last day prior to the public disclosure of Aurora’s intention to pursue a combination with CanniMed.
Background to the Offer
On November 13, 2017, Aurora presented the CanniMed board of directors (the “Board”) with a proposal (the “Proposal”) to explore a mutually agreeable merger on the terms set forth in the Offer, and requested a response prior to 5:00 pm Pacific Time on November 17, 2017 (the “Proposal Deadline”). Although CanniMed’s Board failed to respond to the Proposal prior to the Proposal Deadline, Aurora would still welcome a transaction supported by CanniMed’s Board, and looks forward to engaging with CanniMed’s Board to deliver significant value to CanniMed shareholders. However, at this time, the rationale for the combination is too strong to accept inaction, and thus the decision has been made to proceed to take Aurora’s Offer directly to shareholders.
While we have attempted to engage and have a constructive dialogue with CanniMed’s Board and management about the strong merits of our offer, their refusal to enter into such a discussion, along with the powerful strategic rationale for the combination, leaves us no recourse at this point but to launch a formal offer for the company.
Terry Booth, CEO of Aurora
We believe that CanniMed shareholders would benefit greatly from a combination, not only through the very significant premium we are offering for their shares, but also by participating in Aurora’s continued growth, which is well above our industry peers, and is based on superior business strategy and exceptional, industry-leading execution. We already have the support from a large percentage of CanniMed shareholders, and look forward to bringing this process to a positive conclusion for the benefit of our combined shareholders.
CanniMed’s Highly Conditional Intention to Acquire Newstrike Resources
CanniMed’s announcement late on November 17, 2017 (the “CanniMed Press Release”) of its highly conditional intention to acquire Newstrike Resources Ltd. (“Newstrike Resources” and “Newstrike Resources Offer”) is extremely troubling in light of the bona fide acquisition proposal that Aurora presented to CanniMed’s Board on November 13, 2017. At no point did CanniMed try to engage or otherwise entertain discussions with Aurora regarding the significant offer that had been presented to their Board for CanniMed shareholders prior to entering into the Newstrike Resources agreement.
The Newstrike Resources Offer requires CanniMed shareholders to approve the transaction. Given that 38% of CanniMed shareholders have contractually agreed to support the Aurora Offer and to vote against any proposed action by the CanniMed Board, the Newstrike Resources Offer is a highly conditional proposition with significant uncertainty.
In entering into the highly conditional agreement, CanniMed has agreed to pay a $9.5 million termination fee to Newstrike Resources should a superior proposal, such as the Aurora Offer, emerge. The termination fee, if paid, represents approximately $0.41 cash per share loss to CanniMed shareholders.
The assertion in the CanniMed Press Release that the terms of the Aurora offer “are unknown” is dubious, given that the detailed terms available to CanniMed shareholders were outlined in the proposal delivered by Aurora on November 13, 2017 to the CanniMed Board.
In light of these considerations, it is clear the Newstrike Resources Offer should be considered oppressive to CanniMed shareholders and to Aurora’s Offer, which delivers significantly higher financial and strategic value to CanniMed shareholders. Aurora is reviewing its options with respect to CanniMed’s Newstrike Resources Offer and will comment further in due course.
Compelling Strategic Rationale for the Aurora-CanniMed Combination
Aurora believes that the combination of the two companies is extremely compelling, in the best interest of all shareholders, and will accelerate growth and shareholder value creation for the combined entity, further extending the Company’s leadership position within the global cannabis sector.
Among other things, the combined entity will have:
- Over 40,000 patients – a combined total of over 40,000 active registered cannabis patients in Canada;
- 5 state-of-the-art facilities – significant cultivation capacity with five state-of-the-art facilities;
- 130,000 kg funded capacity – funded capacity of over 130,000 kilograms of annual production, with significant additional capacity planned and funded;
- Expanded international presence – a strengthened international presence with operations and agreements across North America, the European Union, Australia, South Africa, and the Cayman Islands;
- Increased export capacity – multiple EU GMP-compliant production facilities and significantly increased export capacity;
- Increased oil production – high throughput oil production through Aurora’s strategic extraction partner Radient Technologies Inc. to satisfy growing international demand;
- Broader product portfolio – expanded existing and new, near-term product offerings, delivery mechanisms, and devices;
- Strategic product synergies – complementary product offerings which will enable faster market penetration in new sectors for both companies;
- Improved yields – enhanced production yields and product quality through cross-application of proprietary technologies and intellectual property from each of Aurora and CanniMed;
- CanvasRx – immediate ability to address demand growth constraints at CanniMed through CanvasRx’s industry leading physician education and patient counselling services;
- Accelerated growth through innovation – enabling CanniMed to leverage Aurora’s sector leadership in execution, technology integration and innovation to accelerate development and growth potential;
- Genetics – expansion of both companies’ portfolio of genetics;
- eCommerce – enabling CanniMed to leverage Aurora’s unparalleled e-commerce platform, including the only mobile app in Canada that enables customer purchases;
- Same day delivery – expanding Aurora’s same-day delivery service into additional areas across Canada; and
- Strong cash position and balance sheet fueling rapid growth – Aurora`s sector-leading cash position and balance sheet will enable faster roll-out of initiatives for CanniMed to accelerate growth.
Reasons for CanniMed Shareholders to Support the Aurora-CanniMed Combination
- Significant Premium to Market Price. The Offer, based on Aurora’s closing share price of $5.51 on November 17, 2017, will result in CanniMed shareholders receiving the Cap Price of $24.00, which represents a 56.9% premium over the closing price of CanniMed Shares on November 14, 2017, the last day prior to the public disclosure of Aurora’s intention to pursue a combination with CanniMed.
- High Likelihood of Completion. Aurora believes that there is a high likelihood that more than 66 2/3% of the outstanding shares will be tendered to the Offer, and therefore the Offer will be successful, given that the Offer is already supported by 38% of CanniMed shareholders (the “Locked-Up Shareholders”).
- Support of Major Shareholders. 38% of CanniMed shareholders have already agreed to tender their shares in favour of the Offer and are precluded from tendering any of their common shares in favour of any other competing acquisition proposal relating to CanniMed. The Locked-Up Shareholders include CanniMed’s three largest shareholders.
- Continued Participation with an Industry Leader. Aurora has rapidly become a globally dominant cannabis company with a proven track record of exceptional shareholder value creation, with its rapid expansion driven by its agility, innovation and unparalleled execution. The Offer provides CanniMed shareholders the opportunity to continue to participate in the compelling industry growth alongside the established and successful track record of Aurora.
- Increased Scale, Capital Markets Presence and Access to Capital. The pro forma combined company would have a market capitalization of approximately $3 billion, in addition to significantly enhanced liquidity relative to CanniMed, providing greater access to capital. Aurora has cash of more than $340 million upon closing of its two current capital initiatives, relative to only $54 million for CanniMed. Aurora’s capital position provides very significant firepower to continue pursuing its aggressive global expansion and differentiation strategy.
- Potential for Downward Share Price Impact if Offer is Not Accepted. The Offer represents a significant premium to the market price of CanniMed shares prior to the public announcement of Aurora’s interest to acquire CanniMed. Given the the agreements with the Locked-Up Shareholders, CanniMed will be unable to proceed with an alternative competing transaction to the Offer. If the Offer is not successful and no competing transaction is made, Aurora believes it is likely the trading price of CanniMed shares will decline to pre-Offer levels.
Proposed Offer Particulars
Provided Aurora does not uncover or otherwise identify information suggesting that the business, affairs, prospects or assets of CanniMed have been materially impaired, Aurora intends to commence the bid during the week of November 20, 2017 and thereafter mail a takeover bid circular to the registered holders of CanniMed Shares (in the time required under applicable Canadian securities laws). Aurora expects that the Offer, when made, will be remain open for acceptance for at least 105 calendar days from the date of the commencement of the Offer.
Aurora anticipates that the Offer will be subject to a number of customary conditions, including: (i) there being deposited under the Offer, and not withdrawn, at least 66⅔% of the outstanding CanniMed Shares (calculated on a fully diluted basis), excluding any CanniMed Shares held by Aurora; (ii) receipt of all governmental, regulatory and third party approvals that Aurora considers necessary or desirable in connection with the Offer; (iii) no material adverse change having occurred in the business, affairs, prospects or assets of CanniMed; and (iv) the minimum tender and other conditions set out in National Instrument 62-104 Take-Over Bids and Issuer Bids. In addition, Aurora may require the approval of its shareholders to issue the Aurora Shares to be distributed by it in connection with the Offer. If required, Aurora expects that it may call a meeting of its shareholders to consider a resolution to approve the issuance of Aurora Shares in connection with the Offer in early 2018 if required by the policies of the Toronto Stock Exchange.
Intention to Make an Offer
CanniMed shareholders should note that Aurora has not yet commenced the Offer and should carefully review the cautionary statements set out below in this News Release respecting the status of the Offer and the factors that may cause Aurora not to make the Offer.
Aurora may determine not to make the Offer if: (i) it identifies material adverse information concerning the business, affairs, prospects or assets of CanniMed not previously disclosed by CanniMed; (ii) CanniMed implements or attempts to implement defensive tactics (such as a shareholder rights plan, grant of an option (or similar right) to purchase material assets, material acquisitions, issuances of shares (including, a private placement), or increased indebtedness (including, incurrence of significant new liabilities) in relation to the Offer); (iii) CanniMed completes or undertakes to complete any significant transactions, including the proposed, but not yet completed, acquisition of Newstrike Resources Ltd.; or (iv) CanniMed determines to engage with Aurora to negotiate the terms of a combination transaction and Aurora and CanniMed determine to undertake that transaction utilizing a structure other than a takeover bid (a plan of arrangement, for example). Accordingly, there can be no assurance that the Offer will be made or that the final terms of the Offer will be as set out in this News Release.
If Aurora proceeds with the Offer, full details of the Offer will be included in the formal offer and take-over bid circular to be filed with securities regulatory authorities and mailed to shareholders.
This News Release does not constitute an offer to buy or an invitation to sell, or the solicitation of an offer to buy or invitation to sell, any of the securities of Aurora or CanniMed. Such an offer may only be made pursuant to an offer and take-over bid circular filed with the securities regulatory authorities in Canada.
Aurora has retained Canaccord Genuity Corp. as its financial advisor in connection with the Offer. McMillan LLP is acting as the legal advisor to Aurora for the Offer. Laurel Hill Advisory Group has also been retained by Aurora as its information agent in connection with the Offer. Shareholders with questions regarding Aurora’s Offer can contact Laurel Hill at 1-877-452-7184 (or +1-416-304-0211 – collect call for shareholders outside North America).
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as “Aurora Mountain”, a second 40,000 square foot high-technology production facility known as “Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island, and is currently constructing an 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport.
In addition, the Company holds approximately 9.6% of the issued shares (12.9% on a fully-diluted basis) in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens. Aurora’s common shares trade on the TSX under the symbol “ACB”.
Get ahead of the crowd by signing up for 420 Investor when it becomes available again. It’s the largest & most comprehensive premium service for cannabis investors since 2013.